Allogene Therapeutics, Inc.
ALLO
$1.42
-$0.10-6.58%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 0.00 | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 0.00 | -- |
| Cost of Revenue | 31.16M | 40.16M | 50.20M | 44.97M | 44.71M |
| Gross Profit | -31.16M | -40.16M | -50.20M | -44.97M | -44.71M |
| SG&A Expenses | 13.74M | 14.28M | 14.99M | 15.52M | 16.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.90M | 54.44M | 65.19M | 60.49M | 61.05M |
| Operating Income | -44.90M | -54.44M | -65.19M | -60.49M | -61.05M |
| Income Before Tax | -41.40M | -50.94M | -59.73M | -59.50M | -66.29M |
| Income Tax Expenses | -- | -- | -- | 443.00K | -- |
| Earnings from Continuing Operations | -41.40M | -50.94M | -59.73M | -59.94M | -66.29M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.40M | -50.94M | -59.73M | -59.94M | -66.29M |
| EBIT | -44.90M | -54.44M | -65.19M | -60.49M | -61.05M |
| EBITDA | -41.80M | -51.33M | -62.09M | -57.26M | -57.84M |
| EPS Basic | -0.19 | -0.23 | -0.28 | -0.28 | -0.32 |
| Normalized Basic EPS | -0.12 | -0.14 | -0.17 | -0.17 | -0.17 |
| EPS Diluted | -0.19 | -0.23 | -0.28 | -0.28 | -0.32 |
| Normalized Diluted EPS | -0.12 | -0.14 | -0.17 | -0.17 | -0.17 |
| Average Basic Shares Outstanding | 222.04M | 218.93M | 215.36M | 210.57M | 209.19M |
| Average Diluted Shares Outstanding | 222.04M | 218.93M | 215.36M | 210.57M | 209.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |